Nasdaq:US$17.48 (+0.04) | HKEX:HK$27.42 (-0.18) | AIM:£2.54 (+0.07)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 1 Jun 2012

ASCO 2012: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors